Wereport a 48-year-old man with thrombosis of the portal and superior mesenteric vein and inferior vena cava associated with primary antiphospholipid syndrome (APS). Primary APSwas diagnosed by a positive reaction with anticardiolipin antibody (aCL) and the absence of any evidence suggesting the presence of other disease states known to be associated with aCL. A coeliac angiography showed obstruction of the portal and superior mesenteric vein with prominent collaterals and cavernous transformation. Femoral vein angiography showed total obstruction of the external iliac vein and inferior vena cava, and dilation of the pelvic veins, with contrast mediumin the lumbar vein. This case is noteworthy as a report of primary APSaccompanied by extensive abdominal and pelvic venous thrombosis.
Introduction
Antiphospholipid syndrome (APS) is characterized by venous and/or arterial thrombosis in the presence of the lupus anticoagulant, anticardiolipin antibodies (aCL), or both ( 1 , 2) . A variety of venous and arterial occlusions has been documented in patients with APS, including portal and mesenteric vein thrombosis (3) (4) (5) . Wedescribe a patient with primary APS whohad portal and superior mesenteric vein and inferior vena cava thrombosis.Weconsider this patient to be a rare case of primary APSaccompanied by extensive abdominal and pelvic venous thrombosis.
Case Report
A 48-year-old manhad been suffering from intermittent, colicky upper abdominal pain and recurrent edema and ulcers of the lower extremities since 1988. Portal vein thrombosis was observed during an abdominal ultrasound examination in 1992, but no obvious cause could be found. He was diagnosed as having APS based on a high level of antiphospholipid antibody (aPL) in 1999, despite the lack of exact data; prednisolone therapy was initiated by his family doctor. Prednisolone was given orally at an initial dosage of 30 mgfor 8 weeks and then gradually decreased to 15 mg. He was transferred to our hospital in September 2000 because of worsening edemain the lower extremities that had continued for 2 months. He had been diagnosed as having type 2 diabetes mellitus and had been treated by diet alone for the past 12 years. He had a history of smoking for 20 years. No family history of thrombotic disease was present.
Physical examination revealed an ascending venous dilatation in the chest and abdomen,but an enlarged liver or spleen was not palpated. Livedo reticularis, pigmentation and pitting edema were observed on the lower extremities. The results of the laboratory tests obtained at the time of admission are summarized in Table 1 . All blood cell counts, including platelets, were normal. In coagulation tests, the activated partial thromboplastin time (APTT) was normal. His blood chemistry was within the normal range except for high levels of plasma glucose and HbA]c. An anticardiolipin beta 2-glycoprotein I (p2GPI) antibody against complexes of cardiolipin and p2GPI (aCL-(J2GPI antibody) level of 5.0 U/ml was detected using an enzyme-linked immunosorbent assay (ELISA) (aCL p2GPI kit; Yamasa). However, lupus anticoagulant (diluted APTT)and antinuclear antibody tests were negative. Unfortunately, the aCLisotype was not determined. No deficiencies in protein C or protein S were found. An increase in immunoglobulin G and A was observed, but serum levels of C3, C4 and CH50were normal.
Abdominalultrasound examination revealed a normal-sized liver and bands of increased echogenicity surrounding the portal tracts. The portal vein could not be identified. Furthermore, marked atrophy in the right kidney and hypertrophy in the left kidney were observed. Magnetic resonance angiography ( 1) failed to opacify the portal vein and the superior mesenteric vein (SMV), but the marked development of cavernous transformations was observed. Coeliac angiography (Fig. 2) showed obstructions in the portal vein and SMVwith prominent collaterals, cavernous transformation, and drainage into the portal system. Furthermore, a dilated inferior mesenteric vein and coronary vein, which were perfused upstream via esophageal varices, were observed using contrast medium. A selected renal angiography (Fig. 3 ) demonstrated an obstruction in the right renal artery and an absence of contrast mediumin the renal vein or inferior vena cava, with prominent collaterals below the diaphragm. Femoral vein angiography (Fig. 4) via needle penetration in the right femoral vein showed the total obstruction of the external iliac vein and inferior vena cava, and dilated pelvic veins with drainage upstream via the lumbar vein. An endoscopic examination showed esophageal varices with no signs of redness.
The patient was diagnosed as having primary APS associated with the obstruction of the portal vein and superior mesenteric vein, inferior vena cava, and the right renal artery. Other major causes of thrombosis, such as protein C or protein S deficiencies, were excluded. The patient's prescription for prednisolone was continued, due to the effectiveness in lowering the aPL level, and the dose was gradually tapered. However, the precise effect of prednisolone in reducing the aPL level could not be evaluated because data on the aPL level prior to prednisolone administration was not available. Warfarin was simultaneously added to the patient' s prescription. The patient' s diabetes mellitus is presently well controlled with insulin.
Discussion
The patient was diagnosed as having primary APS based on the presence of aCL and the absence of SLEclassification criteria. APS was first proposed by Harris et al (2); the disease is classified as "primary" in the absence of a concurrent autoimmune condition, such as SLE, and as "secondary" in the presence of an autoimmune disorder (6) . Antiphospholipid antibody appears in various clinical states, including SLE and other connective tissue diseases; which have been classified according to their phospholipid reactivity, isotype and co factor requirements (7). The present patient tested positive for aCL-(32GPI antibody. Beta2-GPI is currently considered to be a major antigen of pathogenic aCL. Beta2-GPI is reported to inhibit the ADP-inducedaggregation of platelets and the activation of coagulation factors, and it is considered to control thrombus formation. Anticardiolipin antibody bound to (32GPI may inhibit these antithrombophilic functions and may induce thrombosis (8) . Whereas clinical and animal experimental data clearly suggest the role of (32GPI-dependent aPL in the development of APS, the pathogenesis of this disease is not fully known (9). Vianna et al reported episodes of deep vein thrombosis in 54% ofAPS cases and arterial occulusion in 44% of cases (10) . Vein thrombosis in APSoccurs in veins of various sizes in several locations, with a greater frequency in the veins of the extremities and pulmonary system. Obstruction of the portal vein, mesenteric vein and inferior vena cava has been sporadically reported (5, ll, 12) . The present case is a rare example of combined portal and superior mesenteric vein and inferior vena cava thrombosis in association with primary APS. In this patient, the cause of the extensive venousthrombosis wasthought to be primary APSbecause other major causes of thrombosis were excluded. The development of extensive venous obstructions over a long period of time was possible because of the marked development of collaterals.
The presence of livedo reticularis and ulcers on the lower extremities, as observed in this patient, h?~been associated with recurrent arterial and venous thrombosis. During renal angiography, the absence of contrast mediumin the right renal artery indicated that an arterial occlusion, in addition to the venous occlusion, had also occurred.
According to a recent study, the causes of portal thrombosis, excluding tumor and liver cirrhosis, were as follows: myeloproliferative disorders, protein S and C deficiencies, and APS. APSis thought to be the underlying disorder in 11%of patients with portal thrombosis (13) .
Therapeutic regimens should be developed for the following situations (14): 1) cases where aPL is present but a thrombotic event has not yet occurred, 2) the acute phase, and 3) prevention of further events after a thrombotic event has occurred. Only limited data is available regarding the efficacy of aspirin in preventing initial thrombotic events. For acute phase cases, an appropriate therapeutic methodshould be selected based on the clinical state. In cases of venous and arterial thrombosis, long-term anticoagulant therapy is commonly indicated because of the high recurrence rate and the potential for severe disability and/or death. Khamashta et al (15) reported that a high-intensity regimen of warfarin producing an international normalized ratio (INR) of^3 is effective for the prevention of further thrombotic events. The effectiveness of corticosteroids for the treatment ofAPS is controversial (6) . In this patient, prednisolone was continued because of its previous effectiveness in reducing the aPL level. However, the use of prednisolone to prevent the development of thrombosis in this patient could not be evaluated, even though it was effective in reducing the patient's aPL level.
